Christoph Herbel

Dr. Christoph Herbel is a Group lead CAR T cells for solid cancers at Miltenyi Biotec where he identifies and validates new targets for immune cell–based cancer therapy using the MACSima™ Imaging Platform. Moreover, together with his team he generates new CAR T cells for solid cancers. He performed his doctoral thesis at the German Cancer Research Center (DKFZ) investigating the cross-talk between DNA damage response, metabolism, and epigenetics. Fascinated by this interplay of key cellular processes, he started a postdoc at Dana Farber Cancer Center studying metabolic signaling pathways that influence cellular responses to genotoxic stress. He then worked at Beth Israel Deaconess Medical Center/Harvard Medical School investigating mechanisms and signaling pathways involved in regulation of T cell responses. Dr. Herbel joined Miltenyi Biotec in 2017.